MediWound Ltd. Announces Private Placement of Ordinary Shares

TL;DR

MediWound just did a private share sale, details TBD.

AI Summary

On July 15, 2024, MediWound Ltd. entered into a share purchase agreement for a private placement of ordinary shares with unnamed purchasers. The filing does not specify the number of shares or the total dollar amount of the transaction.

Why It Matters

This private placement indicates the company is raising capital, which could be used for ongoing operations, research and development, or expansion, potentially impacting its future growth and stock value.

Risk Assessment

Risk Level: medium — Private placements can dilute existing shareholders and the lack of specific financial details in this initial filing creates uncertainty.

Key Players & Entities

• MediWound Ltd. (company) — Company entering into the agreement
• July 15, 2024 (date) — Date of the share purchase agreement

FAQ

Key Financial Figures

• $25 million — is expected to raise gross proceeds of $25 million for the Company from the Purchasers, at
• $17.20 — asers, at a price per ordinary share of $17.20. The Private Placement is being effecte
• $15 million — ly with its receipt of an investment of $15 million from Mlnlycke Health Care AB (" Mlnlyck

Filing Documents

• zk2431668.htm (6-K) — 23KB
• exhibit_4-1.htm (EX-4.1) — 182KB
• exhibit_4-2.htm (EX-4.2) — 150KB
• exhibit_4-3.htm (EX-4.3) — 58KB
• exhibit_99-1.htm (EX-99.1) — 19KB
• image00002.jpg (GRAPHIC) — 4KB
• 0001178913-24-002200.txt ( ) — 437KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Entry into PIPE Financing Transaction On July 15, 2024, MediWound, Ltd. (the " Company " or " MediWound ") entered into a share purchase agreement (the " Share Purchase Agreement ") with the purchasers listed on the signature pages thereto (the " Purchasers "), for the offer and sale by the Company to the Purchasers (the " Private Placement ") of ordinary shares, par value NIS 0.07 per share, of the Company (the " ordinary shares "). The Private Placement is expected to raise gross proceeds of $25 million for the Company from the Purchasers, at a price per ordinary share of $17.20. The Private Placement is being effected pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the " Securities Act ") contained in Section 4(a)(2) of and/or Regulation D under the Securities Act. The Company intends to use the net proceeds from the Private Placement, following the payment of fees and expenses, primarily for (i) the advancement of the Company's pre-commercial activities for the Company's EscharEx debridement therapy for the treatment of chronic and other hard-to-heal wounds, (ii) expediting the development of large-scale manufacturing capabilities specifically for EscharEx, and (iii) general corporate purposes. Along with their entry into the Share Purchase Agreement, the Company and the Purchasers entered into a registration rights agreement, dated July 15, 2024 (the " Registration Rights Agreement "), providing the Purchasers with customary registration rights with respect to the ordinary shares to be issued to them pursuant to the Private Placement and any additional Registrable Securities (as defined therein). The Company has agreed to file with the Securities and Exchange Commission (the " SEC "), within 45 days after the closing of the Private Placement, an initial shelf registration statement registering the resale of all Registrable Securities issued in the Private Placement. To the extent that the SEC informs the Company that not all of the Registrable Securities may be registered for resale as a secondary offering on a single registration statement, the Company has agreed to use its reasonable best efforts to file additional shelf registration statement(s) covering the resale of all remaining Registrable Securities not registered in the initial registration statement. The Registration Rights Agreement also provides for payment of liquidated damages by the Company to the Purchasers in the event of certain delays or suspensions in the ability of the Purchasers (or the assignees of their registration rights) to sell Registrable Securities under the Registration Rights Agreement. The agreement further restricts the Company's ability to include for an offering on its own behalf, or on behalf of any of its other security holders (other than the holders under the Registration Rights Agreement, or any security holder with existing rights to include securities in a registration statement), securities in any registration statement filed pursuant to the Registration Rights Agreement— other than securities subject to existing registration rights with respect to which the Company uses reasonable best efforts, but is unsuccessful, to obtain a waiver of such registration rights. The Company may also not file any other registration statements until all Registrable Securities are registered pursuant to a registration statement that is declared effective by the SEC, with customary exceptions. The Registration Rights Agreement also grants customary piggyback registration rights to the Purchasers (or their assignees with rights under the agreement) with respect to any Registrable Securities that have not yet then been registered under registration agreements pursuant to the Registration Rights Agreement. Entry into Collaboration Agreement with PIPE Investor Concurrently with its receipt of an investment of $15 million from Mlnlycke Health Care AB (" Mlnlycke "), a world-leading MedTech company specializing in solutions for wound care and surgical procedures, pursuant to the Private Placement, the Company also entered into a collaboration and rights agreement, dated July 15, 2024, with Mlnlycke (the " Collaboration Agreement "). Under the Collaboration Agreement, MediWound shall be able to benefit from Mlnlycke's comprehensive global expertise in advanced wound care. Accordingly, if requested by MediWound, Mlnlycke

View Full Filing

View this 6-K filing on SEC EDGAR